Last reviewed · How we verify

NCT04152395

Metabolic Syndrome in Patients Undergoing Endovascular Aortic Repair (EVAR)

Status unknown Last updated 27 May 2020
What this trial tests

trial testing EVAR in Metabolic Syndrome in 220 participants. Status unknown.

Timeline
1 June 2020
Primary endpoint
11 December 2021
11 December 2022

Quick facts

Lead sponsorUniversity of Thessaly
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment220
Start date1 June 2020
Primary completion11 December 2021
Estimated completion11 December 2022

Drugs / interventions tested

Conditions studied

Sponsor

University of Thessaly

Who can join

18 and older, any sex, with Metabolic Syndrome or Endovascular Aortic Repair. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective study aims to identify the prevalence of metabolic syndrome in patients undergoing EVAR and the implications of metabolic syndrome on the postoperative outcome, the major complications, the thromboembolic events and the perioperative mortality and morbidity of the patients undergoing vascular surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of EVAR

Trials testing the same drug.

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

Other University of Thessaly trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04152395.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing